% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rajkumar:126390,
      author       = {S. V. Rajkumar and M. A. Dimopoulos and A. Palumbo and J.
                      Blade and G. Merlini and M.-V. Mateos and S. Kumar and J.
                      Hillengass$^*$ and E. Kastritis and P. Richardson and O.
                      Landgren and B. Paiva and A. Dispenzieri and B. Weiss and X.
                      LeLeu and S. Zweegman and S. Lonial and L. Rosinol and E.
                      Zamagni and S. Jagannath and O. Sezer and S. Y. Kristinsson
                      and J. Caers and S. Z. Usmani and J. J. Lahuerta and H. E.
                      Johnsen and M. Beksac and M. Cavo and H. Goldschmidt and E.
                      Terpos and R. A. Kyle and K. C. Anderson and B. G. M. Durie
                      and J. F. S. Miguel},
      title        = {{I}nternational {M}yeloma {W}orking {G}roup updated
                      criteria for the diagnosis of multiple myeloma.},
      journal      = {The lancet / Oncology},
      volume       = {15},
      number       = {12},
      issn         = {1470-2045},
      address      = {London},
      publisher    = {The Lancet Publ. Group},
      reportid     = {DKFZ-2017-02419},
      pages        = {e538 - e548},
      year         = {2014},
      abstract     = {This International Myeloma Working Group consensus updates
                      the disease definition of multiple myeloma to include
                      validated biomarkers in addition to existing requirements of
                      attributable CRAB features (hypercalcaemia, renal failure,
                      anaemia, and bone lesions). These changes are based on the
                      identification of biomarkers associated with near inevitable
                      development of CRAB features in patients who would otherwise
                      be regarded as having smouldering multiple myeloma. A delay
                      in application of the label of multiple myeloma and
                      postponement of therapy could be detrimental to these
                      patients. In addition to this change, we clarify and update
                      the underlying laboratory and radiographic variables that
                      fulfil the criteria for the presence of myeloma-defining
                      CRAB features, and the histological and monoclonal protein
                      requirements for the disease diagnosis. Finally, we provide
                      specific metrics that new biomarkers should meet for
                      inclusion in the disease definition. The International
                      Myeloma Working Group recommends the implementation of these
                      criteria in routine practice and in future clinical trials,
                      and recommends that future studies analyse any differences
                      in outcome that might occur as a result of the new disease
                      definition.},
      keywords     = {Biomarkers, Tumor (NLM Chemicals)},
      cin          = {E013},
      ddc          = {610},
      cid          = {I:(DE-He78)E013-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:25439696},
      doi          = {10.1016/S1470-2045(14)70442-5},
      url          = {https://inrepo02.dkfz.de/record/126390},
}